Podcast
Episode 105 — Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
November 24, 2025
Join the Latham team and guest Eliza Biedziak from Ernst & Young LLP as they discuss what to expect from a government pricing assessment, the role assessments play in compliance, and how assessments can uncover strategic opportunities.
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at Ernst & Young LLP, joins Washington, D.C. partner Chris Schott and associate Danny Machado to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide.
Listen here or subscribe via Apple Podcasts, Spotify, or anywhere else you listen to podcasts.
Read our bi-weekly Drug Pricing Digest or subscribe to receive future editions in your inbox.